Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVTN 320: Safety and Immunogenicity of 426c.Mod.Core-C4b and HxB2.WT.Core-C4b HIV Vaccine Regimen
NCT06796686Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2025
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of 426c.Mod.Core-C4b and HxB2.WT.Core-C4b in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Incidence of Local Signs and Symptoms, Incidence of Systemic Reactogenicity Signs and Symptoms and 5 more. Started Mar 2025; status: recruiting.
02
Drugs
426c.Mod.Core-C4bHxB2.WT.Core-C4b
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06796686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06796686.